Relay Therapeutics Inc (Relay Therapeutics) ) is a clinical-stage precision medicines company that develops oncology and generic drugs. The company's pipeline products include RLY-4008, RLY-2608, GDC-1971, RLY-5836 and GDC-1971 for the treatment of a variety of cancers. Its RLY-4008 is an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), for patients with advanced or metastatic FGFR2-altered solid tumors. The company utilizes the Dynamo platform, which integrates an array of leading-edge computational and experimental approaches designed for drug-protein targets. Relay Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
2nd Floor, 399 Binney Street, Cambridge, Massachusetts, 02139
Website
www.relaytx.com
Telephone
1 617 3708837
No of Employees
323
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RLAY (NASD)
Revenue (2022)
$25.5M
1749.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-17.7%
(2022 vs 2021)
Market Cap*
$807.4M
Net Profit Margin (2022)
XYZ
93.6%
(2022 vs 2021)
* As of and is in US$
Relay Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| RLY-4008 - Cholangiocarcinoma | Dynamo |
| FGFR2 | |
| RLY-5836 | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Relay Therapeutics Inc | Merck & Co Inc | AstraZeneca Plc | Merck KGaA | Eisai Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Germany | Japan |
| City | Cambridge | Kenilworth | Cambridge | Darmstadt | Bunkyo-Ku |
| State/Province | Massachusetts | New Jersey | England | Hessen | Tokyo |
| No. of Employees | 323 | 72,000 | 89,900 | 62,908 | 11,076 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alexis Borisy | Chairman | Executive Board | 2015 | 51 |
| Sanjiv K. Patel, M.D. | Chief Executive Officer; Director; President | Executive Board | 2017 | 49 |
| Tom Catinazzo | Chief Financial Officer | Senior Management | 2022 | 46 |
| Brian R. Adams | Chief Legal Officer | Senior Management | 2022 | 49 |
| Jeanne Gray | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer